The aim of this review is to provide an overview of the physiological basis, clinical picture and treatment options for motion sickness. Motion sickness is a well-known nausea and vomiting syndrome in otherwise healthy people. The physical signs of motion sickness occur in both humans and animals during travel by sea, automobile or airplane and in space. Furthermore, some other special situations, such as simulators, the cinema and video games, have been described as causing pseudomotion sickness. Children between 2 and 12 years old are most susceptible to motion sickness, and women are more frequently affected than men. Predisposing factors include menstruation, pregnancy, migraines and possibly a side difference in the mass of otoconia in the vestibular organs. Therapy is directed towards decreasing conflicting sensory input, accelerating the process of adaptation and controlling nausea and vomiting. To control these vegetative symptoms, scopolamine and antihistamines are the most effective drugs.

Keywords:
Motion sickness, Mechanisms, Prevention, Treatment, Drug treatment
1.
Brandt T, Daroff RB: The multisensory physiological and pathological vertigo syndromes. Ann Neurol 1980;7:195-203.
2.
Oosterveld WJ: Motion sickness. J Travel Med 1995;2:182-185.
3.
Wilson WD: Travel sickness in cattle. Vet Rec 1997;140:76.
4.
Kennedy RS, Graybiel A, McDonough RC, Beckwith FD: Symptomatology under storm conditions in the North Atlantic in control subjects and in persons with bilateral labyrinthine defects. Acta Otolaryngol 1968;66:533-540.
5.
Oman CM: Motion sickness: a synthesis and evaluation of the sensory conflict theory. Can J Physiol Pharmacol 1990;68:294-303.
6.
Reason JT: Motion sickness adaptation: a neural mismatch model. J R Soc Med 1978;71:819-829.
7.
Reason JT, Brand JJ: Motion Sickness. London, Academic Press, 1975.
8.
Schmäl F, Stoll W: Kinetosen. HNO 2000;48:346-356.
9.
Parker DM: A psychophysiological test for motion-sickness susceptibility. J Gen Psychol 1971;85:87-92.
10.
Money KE: Motion sickness. Physiol Rev 1970;50:1-39.
11.
Oman CM: A heuristic mathematical model for the dynamics of sensory conflict and motion sickness. Acta Otolaryngol Suppl 1982;392:1-44.
12.
Pitman JR, Yolton RL: Etiology and treatment of motion sickness: a review. J Am Optom Assoc 1983;54:31-38.
13.
Helling K, Hausmann S, Clarke A, Scherer H: Experimentally induced motion sickness in fish: possible role of the otolith organs. Acta Otolaryngol 2003;123:488-492.
14.
Beier M, Anken RH, Rahmann H: Influence of hypergravity on fish inner ear otoliths. II. Incorporation of calcium and kinetotic behaviour. Adv Space Res 2002;30:727-731.
15.
Hilbig R, Anken RH, Bauerle A, Rahmann H: Susceptibility to motion sickness in fish: a parabolic aircraft flight study. J Gravit Physiol 2002;9:29-30.
16.
Diamond SG, Markham CH: Validating the hypothesis of otolith asymmetry as a cause of space motion sickness. Ann NY Acad Sci 1992;656:725-731.
17.
Nooij SA, Vanspauwen R, Bos JE, Wuyts FL: A re-investigation of the role of utricular asymmetries in space motion sickness. J Vestib Res 2011;21:141-151.
18.
Takabayashi A, Ohmura-Iwasaki T: Functional asymmetry estimated by measurements of otolith in fish. Biol Sci Space 2003;17:293-297.
19.
Xie SJ, Chen W, Jia HB, Wang ZJ, Yao Q, Jiang YY: Ocular vestibular evoked myogenic potentials and motion sickness susceptibility. Aviat Space Environ Med 2012;83:14-18.
20.
Tal D, Hershkovitz D, Kaminski G, Bar R: Vestibular evoked myogenic potential threshold and seasickness susceptibility. J Vestib Res 2006;16:273-278.
21.
Liu L, Yuan L, Wang HB, Yu LS, Zheng J, Luo CQ, Wang Y: The human alpha(2A)-AR gene and the genotype of site -1296 and the susceptibility to motion sickness (in Chinese). Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2002;34:291-297.
22.
Reavley CM, Golding JF, Cherkas LF, Spector TD, MacGregor AJ: Genetic influences on motion sickness susceptibility in adult women: a classical twin study. Aviat Space Environ Med 2006;77:1148-1152.
23.
Shupak A, Gordon CR: Motion sickness: advances in pathogenesis, prediction, prevention, and treatment. Aviat Space Environ Med 2006;77:1213-1223.
24.
Nashner LM, Peters JF: Dynamic posturography in the diagnosis and management of dizziness and balance disorders. Neurol Clin 1990;8:331-349.
25.
Scherer H, Frohlich G: Reactions to coriolis stimulations and postrotatory ENG-response. A study on pilot-candidates and pilots. Acta Otolaryngol 1972;74:113-117.
26.
Scherer H, Helling K, Hausmann S, Clarke AH: On the origin of interindividual susceptibility to motion sickness. Acta Otolaryngol 1997;117:149-153.
27.
Klosterhalfen S, Kellermann S, Pan F, Stockhorst U, Hall G, Enck P: Effects of ethnicity and gender on motion sickness susceptibility. Aviat Space Environ Med 2005;76:1051-1057.
28.
Jokerst MD, Gatto M, Fazio R, Gianaros PJ, Stern RM, Koch KL: Effects of gender of subjects and experimenter on susceptibility to motion sickness. Aviat Space Environ Med 1999;70:962-965.
29.
Grunfeld E, Gresty MA: Relationship between motion sickness, migraine and menstruation in crew members of a ‘round the world' yacht race. Brain Res Bull 1998;47:433-436.
30.
Golding JF, Kadzere P, Gresty MA: Motion sickness susceptibility fluctuates through the menstrual cycle. Aviat Space Environ Med 2005;76:970-973.
31.
Matchock RL, Levine ME, Gianaros PJ, Stern RM: Susceptibility to nausea and motion sickness as a function of the menstrual cycle. Womens Health Issues 2008;18:328-335.
32.
Cheung B, Heskin R, Hofer K, Gagnon M: The menstrual cycle and susceptibility to coriolis-induced sickness. J Vestib Res 2001;11:129-136.
33.
McIntosh IB: Motion sickness - questions and answers. J Travel Med 1998;5:89-91.
34.
Busoni P, Sarti A, Crescioli M, Agostino MR, Sestini G, Banti S: Motion sickness and postoperative vomiting in children. Paediatr Anaesth 2002;12:65-68.
35.
Dichgans J, Brandt T: Visual-vestibular interaction in self-motion perception and postural control; in Teuber L, Held R, Leibowitz HW (eds): Handbook of Sensory Physiology. Springer Verlag Berlin Heidelberg, 1976, vol 5.
36.
Fischer AJ, Oosterveld WJ: Motion sickness (author's transl). HNO 1979;27:285-291.
37.
Yardley L: Motion sickness susceptibility and the utilisation of visual and otolithic information for orientation. Eur Arch Otorhinolaryngol 1990;247:300-304.
38.
Wood R: The ‘haunted swing' illusion. Psychol Rev 1895;2:277-278.
39.
Kubo T, Matsunaga T, Matano S: Correlation between vestibular nuclei and the hypothalamus in the rat. Int J Equilib Res 1974;4:28-36.
40.
Koch KL, Summy-Long J, Bingaman S, Sperry N, Stern RM: Vasopressin and oxytocin responses to illusory self-motion and nausea in man. J Clin Endocrinol Metab 1990;71:1269-1275.
41.
Takeda N, Morita M, Kubo T, Yamatodani A, Watanabe T, Wada H, Matsunaga T: Histaminergic mechanism of motion sickness. Neurochemical and neuropharmacological studies in rats. Acta Otolaryngol 1986;101:416-421.
42.
Wang SC, Chinn H: Experimental motion sickness in dogs: functional importance of chemoreceptive trigger zone. Am J Physiol 1954;111-116.
43.
Nicholson AN, Pascoe PA, Spencer MB, Benson AJ: Jet lag and motion sickness. Br Med Bull 1993;49:285-304.
44.
Griffin MJ, Newman MM: Visual field effects on motion sickness in cars. Aviat Space Environ Med 2004;75:739-748.
45.
Golding JF, Prosyanikova O, Flynn M, Gresty MA: The effect of smoking nicotine tobacco versus smoking deprivation on motion sickness. Auton Neurosci 2011;160:53-58.
46.
Yen Pik Sang FD, Billar JP, Golding JF, Gresty MA: Behavioral methods of alleviating motion sickness: effectiveness of controlled breathing and a music audiotape. J Travel Med 2003;10:108-111.
47.
Ming JL, Kuo BI, Lin JG, Lin LC: The efficacy of acupressure to prevent nausea and vomiting in post-operative patients. J Adv Nurs 2002;39:343-351.
48.
Alkaissi A, Ledin T, Odkvist LM, Kalman S: P6 acupressure increases tolerance to nauseogenic motion stimulation in women at high risk for PONV. Can J Anaesth 2005;52:703-709.
49.
Frey UH, Funk M, Lohlein C, Peters J: Effect of P6 acustimulation on post-operative nausea and vomiting in patients undergoing a laparoscopic cholecystectomy. Acta Anaesthesiol Scand 2009;53:1341-1347.
50.
Frey UH, Scharmann P, Lohlein C, Peters J: P6 acustimulation effectively decreases postoperative nausea and vomiting in high-risk patients. Br J Anaesth 2009;102:620-625.
51.
Barsoum G, Perry EP, Fraser IA: Postoperative nausea is relieved by acupressure. J R Soc Med 1990;83:86-89.
52.
Bertolucci LE, DiDario B: Efficacy of a portable acustimulation device in controlling seasickness. Aviat Space Environ Med 1995;66:1155-1158.
53.
Bruce DG, Golding JF, Hockenhull N, Pethybridge RJ: Acupressure and motion sickness. Aviat Space Environ Med 1990;61:361-365.
54.
O'Brien B, Relyea MJ, Taerum T: Efficacy of P6 acupressure in the treatment of nausea and vomiting during pregnancy. Am J Obstet Gynecol 1996;174:708-715.
55.
Dundee JW, Sourial FB, Ghaly RG, Bell PF: P6 acupressure reduces morning sickness. J R Soc Med 1988;81:456-457.
56.
Hu S, Stritzel R, Chandler A, Stern RM: P6 acupressure reduces symptoms of vection-induced motion sickness. Aviat Space Environ Med 1995;66:631-634.
57.
Stern RM, Jokerst MD, Muth ER, Hollis C: Acupressure relieves the symptoms of motion sickness and reduces abnormal gastric activity. Altern Ther Health Med 2001;7:91-94.
58.
Miller KE, Muth ER: Efficacy of acupressure and acustimulation bands for the prevention of motion sickness. Aviat Space Environ Med 2004;75:227-234.
59.
Bertalanffy P, Hoerauf K, Fleischhackl R, Strasser H, Wicke F, Greher M, Gustorff B, Kober A: Korean hand acupressure for motion sickness in prehospital trauma care: a prospective, randomized, double-blinded trial in a geriatric population. Anesth Analg 2004;98:220-223.
60.
Groen J: Adaptation. Pract Otorhinolaryngol 1957;19:524.
61.
Ruckenstein MJ, Harrison RV: Motion sickness. Helping patients tolerate the ups and downs. Postgrad Med 1991;89:139-144.
62.
Helling K, Westhofen M: Experimental studies of motion sickness on board of a research ship. HNO 1994;42:214-219.
63.
Held R: Exposure history as a factor in maintaining stability of perception and co-ordination. J Nerv Ment Dis 1961;132:26-32.
64.
Cha YH: Mal de débarquement. Semin Neurol 2009;29:520-527.
65.
De Florio PT, Silbergleit R: Mal de débarquement presenting in the emergency department. J Emerg Med 2006;31:377-379.
66.
Cha YH, Brodsky J, Ishiyama G, Sabatti C, Baloh RW: Clinical features and associated syndromes of mal de débarquement. J Neurol 2008;255:1038-1044.
67.
Moeller L, Lempert T: Mal de débarquement: pseudo-hallucinations from vestibular memory? J Neurol 2007;254:813-815.
68.
Takeda N, Morita M, Horii A, Nishiike S, Kitahara T, Uno A: Neural mechanisms of motion sickness. J Med Invest 2001;48:44-59.
69.
Wood CD, Graybiel A: A theory of motion sickness based on pharmacological reactions. Clin Pharmacol Ther 1970;11:621-629.
70.
Gordon CR, Gonen A, Nachum Z, Doweck I, Spitzer O, Shupak A: The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance. J Psychopharmacol 2001;15:167-172.
71.
Murdin L, Golding J, Bronstein A: Managing motion sickness. BMJ 2011;343:d7430.
72.
Schmäl F, Stoll W: Medikamentöse Schwindeltherapie. Laryngorhinootologie 2003;82:44-61.
73.
Matsuoka I, Ito J, Takahashi H, Sasa M, Takaori S: Experimental vestibular pharmacology: a minireview with special reference to neuroactive substances and antivertigo drugs. Acta Otolaryngol Suppl 1984;419:62-70.
74.
Becker G, Goossens H, Seemann K, Souchon F, Weitz T: Prevention of motion sickness with a transdermal therapeutic system containing scopolamine. A randomized, comparative double-blind study in the German Federal Navy (in German). Dtsch Med Wochenschr 1984;109:1881-1885.
75.
Murray JB: Psychophysiological aspects of motion sickness. Percept Mot Skills 1997;85:1163-1167.
76.
Nachum Z, Shahal B, Shupak A, Spitzer O, Gonen A, Beiran I, Lavon H, Eynan M, Dachir S, Levy A: Scopolamine bioavailability in combined oral and transdermal delivery. J Pharmacol Exp Ther 2001;296:121-123.
77.
Klocker N, Hanschke W, Toussaint S, Verse T: Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo. Eur J Pharm Sci 2001;13:227-232.
78.
Simmons RG, Phillips JB, Lojewski RA, Wang Z, Boyd JL, Putcha L: The efficacy of low-dose intranasal scopolamine for motion sickness. Aviat Space Environ Med 2010;81:405-412.
79.
Spinks A, Wasiak J: Scopolamine (hyoscine) for preventing and treating motion sickness. Cochrane Database Syst Rev 2011;6:CD002851.
80.
Gil A, Nachum Z, Tal D, Shupak A: A comparison of cinnarizine and transdermal scopolamine for the prevention of seasickness in naval crew: a double-blind, randomized, crossover study. Clin Neuropharmacol 2012;35:37-39.
81.
Gray L, Carliner P: The prevention and treatment of motion sickness. Science 1949;109:359.
82.
Wood CD, Kennedy RE, Graybiel A, Trumbull R, Wherry RJ: Clinical effectiveness of anti-motion-sickness drugs. Computer review of the literature. JAMA 1966;198:1155-1158.
83.
Valoti M, Frosini M, Dragoni S, Fusi F, Sgaragli G: Pharmacokinetics of diphenhydramine in healthy volunteers with a dimenhydrinate 25 mg chewing gum formulation. Methods Find Exp Clin Pharmacol 2003;25:377-381.
84.
Buckey JC, Alvarenga D, Cole B, Rigas JR: Chlorpheniramine for motion sickness. J Vestib Res 2004;14:53-61.
85.
Buckey JC Jr, Alvarenga DL, MacKenzie TA: Chlorpheniramine and ephedrine in combination for motion sickness. J Vestib Res 2007;17:301-311.
86.
Weinstein SE, Stern RM: Comparison of marezine and dramamine in preventing symptoms of motion sickness. Aviat Space Environ Med 1997;68:890-894.
87.
Cheung BS, Heskin R, Hofer KD: Failure of cetirizine and fexofenadine to prevent motion sickness. Ann Pharmacother 2003;37:173-177.
88.
Stoot J: Mechanism and treatment of motion sickness; in Davis C, Lake Bakaar G, Grahame-Smith D (eds): Nausea and vomiting: mechanisms and treatment. Berlin, Springer, 1986.
89.
Ramanathan R, Geary RS, Bourne DW, Putcha L: Bioavailability of intranasal promethazine dosage forms in dogs. Pharmacol Res 1998;38:35-39.
90.
Cowings PS, Toscano WB, De Roshia C, Miller NE: Promethazine as a motion sickness treatment: impact on human performance and mood states. Aviat Space Environ Med 2000;71:1013-1022.
91.
Huang M, Gao JY, Zhai ZG, Liang QL, Wang YM, Bai YQ, Luo GA: An HPLC-ESI-MS method for simultaneous determination of fourteen metabolites of promethazine and caffeine and its application to pharmacokinetic study of the combination therapy against motion sickness. J Pharm Biomed Anal 2012;62:119-128.
92.
Kohl RL: Failure of metoclopramide to control emesis or nausea due to stressful angular or linear acceleration. Aviat Space Environ Med 1987;58:125-131.
93.
Oman CM, Lichtenberg BK, Money KE, McCoy RK: MIT/Canadian vestibular experiments on the Spacelab-1 mission. 4. Space motion sickness: symptoms, stimuli, and predictability. Exp Brain Res 1986;64:316-334.
94.
Rubio S, Weichenthal L, Andrews J: Motion sickness: comparison of metoclopramide and diphenhydramine to placebo. Prehosp Disaster Med 2011;26:305-309.
95.
Hershkovitz D, Asna N, Shupak A, Kaminski G, Bar R, Tal D: Ondansetron for the prevention of seasickness in susceptible sailors: an evaluation at sea. Aviat Space Environ Med 2009;80:643-646.
96.
Muth ER, Elkins AN: High dose ondansetron for reducing motion sickness in highly susceptible subjects. Aviat Space Environ Med 2007;78:686-692.
97.
Levine ME, Chillas JC, Stern RM, Knox GW: The effects of serotonin (5-HT3) receptor antagonists on gastric tachyarrhythmia and the symptoms of motion sickness. Aviat Space Environ Med 2000;71:1111-1114.
98.
Marcus DA, Furman JM, Balaban CD: Motion sickness in migraine sufferers. Expert Opin Pharmacother 2005;6:2691-2697.
99.
Drummond PD: Effect of tryptophan depletion on symptoms of motion sickness in migraineurs. Neurology 2005;65:620-622.
100.
Marcus DA, Furman JM: Prevention of motion sickness with rizatriptan: a double-blind, placebo-controlled pilot study. Med Sci Monit 2006;12:I1-I7.
101.
Furman JM, Marcus DA, Balaban CD: Rizatriptan reduces vestibular-induced motion sickness in migraineurs. J Headache Pain 2011;12:81-88.
102.
Wang JJ, Dutia MB: Effects of histamine and betahistine on rat medial vestibular nucleus neurones: possible mechanism of action of anti-histaminergic drugs in vertigo and motion sickness. Exp Brain Res 1995;105:18-24.
103.
Gordon CR, Doweck I, Nachum Z, Gonen A, Spitzer O, Shupak A: Evaluation of betahistine for the prevention of seasickness: effect on vestibular function, psychomotor performance and efficacy at sea. J Vestib Res 2003;13:103-111.
104.
Matsnev EI, Sigaleva EE: Efficacy of histaminergic drugs in experimental motion sickness. J Vestib Res 2007;17:313-321.
105.
Albert EG: Phenytoin for the prevention of motion sickness. Med J Aust 2003;178:575-576.
106.
Otto B, Riepl RL, Otto C, Klose J, Enck P, Klosterhalfen S: μ-Opiate receptor agonists - a new pharmacological approach to prevent motion sickness? Br J Clin Pharmacol 2006;61:27-30.
107.
Cohen B, Dai M, Yakushin SB, Raphan T: Baclofen, motion sickness susceptibility and the neural basis for velocity storage. Prog Brain Res 2008;171:543-553.
108.
Conder GA, Sedlacek HS, Boucher JF, Clemence RG: Efficacy and safety of maropitant, a selective neurokinin 1 receptor antagonist, in two randomized clinical trials for prevention of vomiting due to motion sickness in dogs. J Vet Pharmacol Ther 2008;31:528-532.
109.
Hickman MA, Cox SR, Mahabir S, Miskell C, Lin J, Bunger A, McCall RB: Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats. J Vet Pharmacol Ther 2008;31:220-229.
110.
Lee JA, Watson LA, Boothby G: Calcium antagonists in the prevention of motion sickness. Aviat Space Environ Med 1986;57:45-48.
111.
Doweck I, Gordon CR, Spitzer O, Melamed Y, Shupak A: Effect of cinnarizine in the prevention of seasickness. Aviat Space Environ Med 1994;65:606-609.
112.
Shupak A, Doweck I, Gordon CR, Spitzer O: Cinnarizine in the prophylaxis of seasickness: laboratory vestibular evaluation and sea study. Clin Pharmacol Ther 1994;55:670-680.
113.
Jia L, Wang WY, Zhou LM, Mo FF, Li M: Antimotion sickness effects of ginsenosides combined with dexamethasone in rats (in Chinese). Zhong Xi Yi Jie He Xue Bao 2010;8:358-362.
114.
Lucertini M, Mirante N, Casagrande M, Trivelloni P, Lugli V: The effect of cinnarizine and cocculus indicus on simulator sickness. Physiol Behav 2007;91:180-190.
115.
Grontved A, Brask T, Kambskard J, Hentzer E: Ginger root against seasickness. A controlled trial on the open sea. Acta Otolaryngol 1988;105:45-49.
116.
Holtmann S, Clarke AH, Scherer H, Hohn M: The anti-motion sickness mechanism of ginger. A comparative study with placebo and dimenhydrinate. Acta Otolaryngol 1989;108:168-174.
117.
Mowrey DB, Clayson DE: Motion sickness, ginger, and psychophysics. Lancet 1982;i:655-657.
118.
Lien HC, Sun WM, Chen YH, Kim H, Hasler W, Owyang C: Effects of ginger on motion sickness and gastric slow-wave dysrhythmias induced by circular vection. Am J Physiol Gastrointest Liver Physiol 2003;284:G481-G489.
119.
Chrubasik S, Pittler MH, Roufogalis BD: Zingiberis rhizoma: a comprehensive review on the ginger effect and efficacy profiles. Phytomedicine 2005;12:684-701.
120.
Nicholson AN, Stone BM, Turner C, Mills SL: Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med 2002;73:570-574.
121.
Paul MA, MacLellan M, Gray G: Motion-sickness medications for aircrew: impact on psychomotor performance. Aviat Space Environ Med 2005;76:560-565.
122.
Seibel K, Schaffler K, Reitmeir P, Golly I: A randomised, placebo-controlled study comparing two formulations of dimenhydrinate with respect to efficacy in motion sickness and sedation. Arzneimittelforschung 2002;52:529-536.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.